CSL Seqirus (CSL)

Executive Summary

CSL Seqirus, a business unit of CSL Limited, is a premier global influenza vaccine provider with state-of-the-art manufacturing facilities across the US, UK, and Australia. The company supplies approximately one in four doses of seasonal flu vaccines worldwide, leveraging its proprietary cell-based (Flucelvax) and adjuvanted (Fluad) technologies that offer improved efficacy over traditional egg-based alternatives. Its strong operational footprint and established relationships with governments and public health agencies ensure a stable revenue stream from recurring seasonal demand and pandemic preparedness contracts. CSL Seqirus is also investing heavily in next-generation vaccine platforms, including mRNA and combination vaccines, to address evolving viral threats and expand its portfolio beyond influenza. Key upcoming catalysts for CSL Seqirus include late-stage clinical data readouts for its novel mRNA-based influenza vaccine candidate, which could revolutionize annual flu prevention through more rapid and scalable manufacturing. Additionally, the company is poised to secure expanded pandemic preparedness contracts with the US and other governments, reinforcing its role as a critical partner in global health security. Regulatory submissions for an enhanced flu vaccine formulation in Japan and other Asian markets could open new high-growth geographies. With a robust pipeline and strong commercial execution, CSL Seqirus is well-positioned to sustain growth, though it faces competition from emerging mRNA flu vaccines and potential vaccine fatigue among the public.

Upcoming Catalysts (preview)

• H2 2026Phase 3 data readout for mRNA-based influenza vaccine candidate60% success
• 2026Expanded pandemic preparedness contract with US BARDA70% success
• Q3 2026Regulatory submission acceptance for next-generation influenza vaccine in Japan80% success